SyncAI.news, a Varaisys broadcasting
Can AI help scientists identify promising drug candidates?
ON

OpenAI News

· 1 min read

AI LabsOpenAI News

Can AI help scientists identify promising drug candidates?

We’re introducing MedChemBench, a benchmark that evaluates AI models on reasoning tasks drawn from medicinal chemistry research. It tests whether models can connect a molecule’s structure with experimental evidence to explain results, compare compounds, and predict their properties. Building AI that can reliably support this work is one step towards helping scientists develop better medicines.

One of the hardest parts of this work is that improving one property of a molecule can make another worse. A compound might act strongly against a disease related protein but be poorly absorbed or break down too quickly in the body. Medicinal chemists work through these tradeoffs by designing, making, and testing related compounds, then deciding what to try next. For AI to help, it needs to connect changes in molecular structure with experimental evidence and reason about what compounds are worth pursuing.

MedChemBench measures these abilities through 99 problems drawn from published research. At the xhigh reasoning setting, GPT‑6.2 Astra earned 84.5% of the available credit, compared with 83.3% for GPT‑6 Astra, 82.0% for GPT‑6.1 Sol, and 58.2% for GPT‑5.6 Sol. GPT‑6 Astra was strongest at reconstructing molecular structures and explaining experimental evidence. Selecting compounds and predicting their numerical properties proved harder for that model.

What MedChemBench grades

MedChemBench draws on 117 papers and patents and includes 761 distinct molecular structures. For most problems, models receive the context available at a chosen point in a research program: the biological target, the researchers’ goals, the compounds studied so far, and selected experimental findings.

The benchmark evaluates four components:

Prediction across competing properties

Later experiments, withheld from the model, showed a tradeoff. Compound 23 blocked PRMT5 in cells at a lower concentration, while compound 24 crossed the cell barrier more readily and broke down more slowly in the liver-enzyme assay.

Original source

This story was published by OpenAI News. SyncAI.news shows a preview; the complete article is on the publisher's site.

Read the full story on openai.com

Similar News